Pfizer Sep 23, 2022 NICE Recommends Pfizer's Ibrance Combination for HER2-Negative Breast Cancer Sep 20, 2022 Transcriptomics Plus 'Immune Tolerance' of Normal Tissue Shows Promise in Lung Cancer Prognosis Premium Sep 10, 2022 Lilly's Verzenio Extends Five-Year Breast Cancer Survival, Adds to Debate Over Best CDK4/6 Inhibitor Aug 29, 2022 Novartis' Scemblix Nets European Approval for Subset of CML Patients Jul 28, 2022 Pfizer Reports Q2 US Sales Growth for Ibrance Despite Declines in Other Markets, Greater Competition Premium Jul 28, 2022 Canadian Nurse Navigator-Led Program Aims to Improve Breast Cancer Genomic Test Access Premium Jul 19, 2022 Kisqali Shines as Novartis Posts Slight Decline in Q2 Revenues Jul 15, 2022 Pfizer's Xalkori Gets FDA Approval for ALK-Positive Inflammatory Myofibroblastic Tumors Jun 6, 2022 Oncologists Debate Suitability of CDK4/6 Inhibitors at ASCO Given Long-Term Ibrance Data Premium Jun 2, 2022 OnKure Begins Phase Ib/II Trial of HDAC Inhibitor, Pfizer's Mektovi in NRAS-Mutated Melanoma May 11, 2022 Strata Oncology Enrolling Patients in Basket Trial Exploring Biomarker-Defined Indications May 4, 2022 ESMO Breast Cancer Symposium Data Support First-Line CDK4/6 Inhibitor Combinations Premium May 3, 2022 Pfizer's Oncology Business Grows Sales 4 Percent in Q1 Mar 31, 2022 Second-Generation CDK Inhibitors Aim to Address CDK4/6 Resistance in Breast Cancer Premium Mar 18, 2022 In Brief This Week: Ideaya Biosciences, Pfizer, Strata Oncology, Qualigen Therapeutics Feb 24, 2022 Amoy Diagnostics, Pierre Fabre Collaborate to Develop CDx in China Feb 8, 2022 Pfizer Q4 Oncology Revenues Grow Seven Percent Despite Ibrance, Xalkori Slowdowns Jan 28, 2022 Pfizer's Lorviqua Approved in EU for First-Line Treatment of ALK-Positive Advanced Lung Cancer Nov 18, 2021 Pfizer Makes $15M Equity Investment in Cardiff Oncology Nov 17, 2021 Imugene to Begin Phase II Trial of B-Cell Immunotherapy in HER2-Postive Gastric Cancer Load More Breaking News Dragonfly Therapeutics Begins Phase II Trial of HER2-Targeted NK-Cell Engager Touchlight to Provide DNA Vector for Odimma Therapeutics' Personalized Neoantigen Vaccine Trial FDA Approves Thermo Fisher HLA Typing Test as CDx for Immunocore Uveal Melanoma Therapy Caris Life Sciences, Hummingbird Bioscience Partner on Anti-HER3 Therapy Advancement Akeso, Summit Therapeutics Ink $5B Licensing Deal for PD-1/VEGF Bispecific Antibody Bluestar Genomics to Study Pancreatic Cancer Early Detection Test in Type 2 Diabetes Patients
